Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 6/20 | 0.45 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.42 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.42 |
| ▸ | PKN2 | Q16513 | 3/20 | 0.42 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | CHUK | O15111 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | LTK | P29376 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22346275 | 1.00 | MDM2 (0.45) | MDM2ROCK2ROCK1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL22346419 | 0.98 | ROCK2 (0.46) | MDM2ROCK2ROCK1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL22346417 | 0.98 | ROCK2 (0.46) | MDM2ROCK2ROCK1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL16498370 | 0.88 | AAK1 (0.50) | ROCK2ROCK1CYP3A4MAPK1AURKB | |
| SCHEMBL503278 | 0.82 | GAA (0.47) | MDM2ROCK2ROCK1AURKBPRKX | |
| SCHEMBL60778 | 0.82 | GAA (0.47) | MDM2ROCK2ROCK1AURKBPRKX | |
| SCHEMBL60777 | 0.82 | GAA (0.47) | MDM2ROCK2ROCK1AURKBPRKX | |
| Hydrochloric Acid SCHEMBL9474603 | 0.81 | MDM2 (0.42) | MDM2ROCK2ROCK1CYP3A4MAPK1 | |
| Hydrochloric Acid SCHEMBL3817699 | 0.81 | MDM2 (0.42) | MDM2ROCK2ROCK1CYP3A4MAPK1 | |
| Hydrochloric Acid SCHEMBL9474612 | 0.81 | MDM2 (0.42) | MDM2ROCK2ROCK1CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4398987-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC Therapeutics, Inc. (US) | 2024-07-17 | — | — | EP | claimed |
| WO-2023039369-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | WO | claimed |
| EP-3924049-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC Therapeutics, Inc. (US) | 2021-12-22 | — | — | EP | claimed |
| WO-2020167628-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2020-08-20 | — | — | WO | claimed |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | PTC THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20240390338-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | PTC THERAPEUTICS, INC. | 2024-11-28 | — | — | US | disclosed |
| US-20240051968-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | PTC THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | PTC THERAPEUTICS, INC. (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135586-A1 | THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA | SF3B5, SF3B2, SF3B1 | MDM2 4777/4885ROCK2 4272/4885ROCK1 4486/4885 |
| US-20240051968-A1 | METHODS FOR TREATING SPINOCEREBELLAR ATAXIA TYPE 3 | ATXN2, ATXN10, ATXN2L | MDM2 4430/4885ROCK2 2284/4885ROCK1 3202/4885 |
| US-12384797-B2 | Thioeno[3,2-b] pyridin-7-amine compounds for treating familial dysautonomia | SF3B5, SF3B2, SF3B1 | MDM2 4777/4885ROCK2 4272/4885ROCK1 4486/4885 |
| US-20240390338-A1 | METHODS FOR TREATING NEUROGENERATIVE DISEASES | MAPT, MAP1B, MAP2 | MDM2 3691/4885ROCK2 974/4885ROCK1 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.